My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

JPMorgan Active Growth ETF (NY:JGRO)

93.49 UNCHANGED

Streaming Delayed Price Updated: 8:00 PM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about JPMorgan Active Growth ETF

< Previous 1 2 3 Next >

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week ↗

August 13, 2025

The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.

Via Stocktwits

Texas Sues Eli Lilly Over Bribery Allegations: Retail Focuses On Company’s Upbeat Performance ↗

August 12, 2025

Texas Attorney General Ken Paxton alleged that Lilly offered illegal incentives to medical providers in Texas designed to steer providers toward prescribing Lilly’s drugs.

Via Stocktwits

Gilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned Exuberant ↗

August 08, 2025

Via Stocktwits

US Regulator Grants Exemption For Zoox Vehicles To Be On Road Without Compliance With Federal Standards ↗

August 06, 2025

Via Stocktwits

BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive ↗

July 28, 2025

The Supreme Court's Braidwood decision only concretized the power of the Department of Health and Human Services to decide what is necessary preventative care, rather than outright protecting...

Via Stocktwits

Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet ↗

July 25, 2025

Needham has a $133 price target on the stock, representing an upside of about 17.5% to the stock’s closing price on Thursday.

Via Stocktwits

Topics Workforce

Abbott Stock Slips On Disappointing Q3 Earnings Forecast: Retail Chatter Rises Over 200% In 24 Hours ↗

July 17, 2025

Abbott’s sales of continuous glucose monitors were $1.9 billion in the second quarter, marking a growth of 21.4% on a reported basis, the company said.

Via Stocktwits

Topics Artificial Intelligence

AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers ↗

July 10, 2025

Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China.

Via Stocktwits

Topics Product Recall

Intuitive Surgical Gets FDA Clearance For Advanced Energy Surgical Instrument: Retail Sentiment Improves ↗

July 10, 2025

Vessel Sealer Curved is a fully wristed, advanced bipolar electrosurgical instrument designed to seal, cut, grasp, and dissect tissue for use with Intuitive’s da Vinci surgical systems.

Via Stocktwits

Crumly Loads Up on 110,675 SDVY Shares in Q2 Filing ↗

July 09, 2025

Crumly & Associates Inc. reported purchasing 110,675 shares of SDVY valued at $3.81 million in Q2 2025, according to a July 2 SEC filing.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Gilead, Global Fund Enter Agreement To Supply HIV Prevention Drug To Low & Lower-Middle-Income Countries ↗

July 09, 2025

Under the agreement, Gilead will supply enough doses of its Lenacapavir drug to reach up to two million people over three years in countries supported by the Global Fund, at no profit to the company.

Via Stocktwits

Eli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After Study Shows Reduced Side Effects ↗

July 09, 2025

The U.S. FDA approved Kisunla, an amyloid-targeting therapy, in July 2024 after a study showed that it significantly slowed cognitive and functional decline in Alzheimer’s patients who were less...

Via Stocktwits

Johnson & Johnson Submits Supplemental Drug Application To FDA For Schizophrenia Drug Caplyta ↗

July 08, 2025

J&J gained access to Caplyta by the acquisition of Intra-Cellular Therapies, Inc., which was completed in April.

Via Stocktwits

Topics Government

AbbVie To Acquire Capstan Therapeutics For Up To $2.1 Billion To Boost Immunology Portfolio As Humira Sales Drop: Stock Gains In Morning Trade ↗

June 30, 2025

The acquisition will include Capstan’s lead asset, called CPTX2309, in development for the treatment of B-cell-mediated autoimmune diseases.

Via Stocktwits

Topics Intellectual Property

Gilead Stock Rises On US Supreme Court Ruling In Favor Of Health Insurers Covering Preventive Care ↗

June 27, 2025

Jefferies termed the Supreme Court’s ruling an ‘incremental positive’ for Gilead that removes an overhang going into the launch for Yeztugo.

Via Stocktwits

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.